Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113034 · ClinicalTrials.gov registry record · Phase 1
A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
A Phase 1 study of Asthma and Bronchiectasis, sponsored by Ansun Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01113034 is a Phase 1 study of Asthma and Bronchiectasis that has completed, run by Ansun Biopharma. The registered enrollment target is 11 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01113034, a Phase 1 study of Asthma and Bronchiectasis, has completed, sponsored by Ansun Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to evaluate whether DAS181 is safe in subjects with well-controlled asthma or bronchiectasis.
Conditions Studied
Interventions
- DRUG DAS181 dry powder, formulation F02
- DRUG Respitose ML006 (DMV-Fonterra)
Study Locations (1)
Maryland
- NIH Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01113034
The ClinicalTrials.gov registry entry for NCT01113034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The listed sponsor is Ansun Biopharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which DAS181 dry powder, formulation F02 is the first listed.
NCT01113034 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01113034 about?
NCT01113034 is a clinical study titled "A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis". The primary objective is to evaluate whether DAS181 is safe in subjects with well-controlled asthma or bronchiectasis.
What is the current status of trial NCT01113034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2010-07. Estimated completion is 2011-08-22.
What conditions does trial NCT01113034 study?
This clinical trial studies the following conditions: Asthma, Bronchiectasis.
What interventions are being tested in trial NCT01113034?
The interventions under investigation include: DAS181 dry powder, formulation F02 (DRUG), Respitose ML006 (DMV-Fonterra) (DRUG).
Who is sponsoring clinical trial NCT01113034?
This trial is sponsored by Ansun Biopharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01113034 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.